Janssen

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL
Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL
Pharmaceutical Business Review
Janssen
JNJ
EMA
Imbruvica
CLL
Flag link:
J&J, RoosterBio and Element Kick Off 2020 with Expansions
J&J, RoosterBio and Element Kick Off 2020 with Expansions
BioSpace
JNJ
Janssen
R&D
Rooster Bio
Element Biosciences
Flag link:
Janssen Expands Research & Development Presence with Major Investment in South San Francisco
Janssen Expands Research & Development Presence with Major Investment in South San Francisco
AP
JNJ
Janssen
R&D
San Francisco
Flag link:
Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated
Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated
Stat
Donald Trump
veterans
esketamine
major depression
Spravato
JNJ
Janssen
Flag link:
After midstage flop, Janssen says thanks but no thanks to Provention Bio drug
After midstage flop, Janssen says thanks but no thanks to Provention Bio drug
Fierce Biotech
Janssen
Provention Bio
Crohn’s disease
PRV-6527
JNJ
Flag link:
Digital health in 2019 – an increasingly mature sector
Digital health in 2019 – an increasingly mature sector
Pharmaforum
digital health
Germany
Janssen
Apple
Google
FDA
Amazon
Flag link:
XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B
XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B
Seeking Alpha
Xbiotech
JNJ
Janssen
bermekimab
Flag link:
Janssen taps wearable tech in Invokana heart failure trial
Janssen taps wearable tech in Invokana heart failure trial
Pharmaforum
JNJ
Janssen
Invokana
heart failure
wearables
real world evidence
clinial trials
Flag link:
Janssen’s Stelara Wins FDA Approval for Ulcerative Colitis
Janssen’s Stelara Wins FDA Approval for Ulcerative Colitis
BioSpace
JNJ
Janssen
Stelara
FDA
ulcerative colitis
Flag link:
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
BioSpace
JNJ
Janssen
Tremfya
clinical trials
psoriasis
Flag link:
J&J Will Appeal $8 Billion Verdict of Claims Risperdal Caused Breast Growth
J&J Will Appeal $8 Billion Verdict of Claims Risperdal Caused Breast Growth
BioSpace
JNJ
Janssen
Risperdal
Flag link:
J&J adds 200 jobs with new biopharma plant at site in Ireland
J&J adds 200 jobs with new biopharma plant at site in Ireland
Fierce Pharma
JNJ
Janssen
Ireland
drug manufacturing
hirings
Flag link:
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Marketwatch
JNJ
Janssen
tuberculosis
HIV
philanthropy
Flag link:
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
BioSpace
Erleada
Janssen
JNJ
ESMO
prostate cancer
Flag link:
Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO
Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO
Fierce Biotech
gene therapy
Passage Bio
Janssen
Flag link:
Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed
Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed
Drug Channels
Eli Lilly
Janssen
Merck
Novartis
Sanofi
drug pricing
Flag link:
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Pharmaforum
JNJ
Janssen
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
J&J gets Stelara okay in Europe for ulcerative colitis
J&J gets Stelara okay in Europe for ulcerative colitis
Pharmaforum
JNJ
Stelara
Janssen
Europe
Flag link:
Companies file suit in Canada challenging new rules to lower drug prices
Companies file suit in Canada challenging new rules to lower drug prices
Yahoo/Reuters
drug pricing
Canada
Janssen
Merck
Bayer
Servier
Boehringer Ingelheim
Flag link:
Janssen gets EC approval for two new indications of Imbruvica
Janssen gets EC approval for two new indications of Imbruvica
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
Waldenström’s macroglobulinemia
chronic lymphocytic leukemia
Flag link:

Pages